11th Best of ASCO® 2016 In Lebanon

Collective Wisdom 2016
The Future of Patient-Centered Care and Research

Organized by Lebanese Society of Medical Oncology
Licensed by The American Society of Clinical Oncology
Endorsed by The Arab Medical Association Against Cancer

September 2 - 3, 2016
Phoenicia Hotel, Beirut - Lebanon

Register now at www.bestofasco.org
Friday 2nd of September 2016

08:00  Registration

09:00 - 10:00  Hematologic Malignancies - Lymphoma &
Chronic Lymphocytic Leukemia

**Speakers:** TBA

**Chairs:** TBA

- **Abstract 7501:** A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab (moga) vs investigator's choice (IC) in the treatment of patients (pts) with relapsed/refractory (R/R) adult t-cell leukemia-lymphoma (ATL). **Adrienne Alise Phillips, MD**

- **Abstract 7503:** Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase 2 study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). **Mathias J. Rummel, MD**

- **Abstract 7504:** Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study. **Pieternella J. Lugtenburg, MD**

- **Abstract 7506:** PILLAR-2: A randomized, double-blind, placebo-controlled, phase 3 study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL). **Thomas E. Witzig, MD**

- **Abstract 7508:** A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma. **Steven I. Park, MD**
Friday 2\textsuperscript{nd} of September 2016

10:00 - 10:45  Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, & Allotransplant

Speakers:  TBA  
Chairs:  TBA

- **Abstract 7000**: Phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. **Jeffrey E. Lancet, MD**

- **Abstract 7001**: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: Results from the ENESTfreedom study. **Andreas Hochhaus, MD**

- **Abstract 7008**: Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. **Jorge E. Cortes, MD**

- **Abstract 7009**: Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients \( \geq 65 \) years ineligible for standard induction therapy. **Daniel Aaron Pollyea, MD**
Friday 2nd of September 2016

10:45 - 11:30  Hematologic Malignancies - Plasma Cell Dyscrasia

*Speakers:* TBA  
*Chairs:* TBA

- **Abstract 8000:** Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM Trial). **Michele Cavo, MD**

- **Abstract 8001:** Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS). **Michel Attal, MD**

- **Abstract 8003:** Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients. **Sham Mailankody, MD**

- **Abstract 8009:** A Phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from 2 new dose cohorts. **Ravi Vij, MD**

- **Abstract LBA4:** Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. **Antonio Palumbo, MD**

11:30 - 12:00  Coffee Break
Friday 2\textsuperscript{nd} of September 2016

12:00 - 13:00 \hspace{1cm} Breast Cancer - HER2/ER+

\textit{Speakers:} TBA  
\textit{Chairs:} TBA

- **Abstract LBA1:** A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. \textit{Paul E. Goss, MD}

- **Abstract 500:** Pathologic complete response rates after neoadjuvant trastuzumab emtansine (T-DM1) + pertuzumab vs docetaxel + carboplatin + trastuzumab + pertuzumab treatment in patients with HER2-positive early breast cancer (KRISTINE). \textit{Sara A. Hurvitz, MD}

- **Abstract LBA503:** Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O vs Herceptin. \textit{Hope S. Rugo, MD}

- **Abstract 507:** PALOMA-2: Primary results from a phase 3 trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). \textit{Richard S. Finn, MD}

- **Abstract 512:** Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA). \textit{Nicholas C. Turner, MD}

13:00 - 14:00 \hspace{1cm} Lunch Break
Friday 2\textsuperscript{nd} of September 2016

14:00 - 15:00  Breast Cancer - Triple-Negative / Cytotoxic Chemotherapy / Local Therapy

Speakers: TBA
Chairs: TBA

- **Abstract LBA509**: Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results. **Aditya Bardia, MD**

- **Abstract 1000**: Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer. **Atilla Soran, MD**

- **Abstract 1005**: A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). **Ravi Vij, MD**

- **Abstract 1007**: Ten-year survival results of ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1–2 N0 M0 breast cancer who have a positive sentinel node (Alliance). **Armando E. Giuliano, MD**
Friday 2\textsuperscript{nd} of September 2016

15:00 - 16:00  \textbf{Lung Cancer - Non-Small Cell Metastatic}

\textit{Speakers:} TBA
\textit{Chairs:} TBA

- \textbf{Abstract 108:} Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). \textit{Alexander E. Drilon, MD}

- \textbf{Abstract 9004:} Local Consolidative Therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study. \textit{Daniel Richard Gomez, MD}

- \textbf{Abstract 9008:} Primary analysis for alectinib versus crizotinib in ALK-inhibitor naïve ALK positive non-small cell lung cancer (ALK+ NSCLC) in randomized open-label phase III trial (J-ALEX study). \textit{Hiroshi Nokihara, MD}

- \textbf{Abstract 9012:} A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): LURET study. \textit{Takashi Seto, MD}

11:30 - 12:00  \textbf{Coffee Break}
Friday 2nd of September 2016

16:00 - 16:45  Lung Cancer - Non-small Cell / Small Cell / Other Thoracic Cancers

Speakers: TBA
Chairs: TBA

- **Abstract 8500:** Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer. Zhongxing X. Liao, MD

- **Abstract 8504:** CONVERT: An international randomised controlled trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy (RT) schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS) (NCT00433563). Corinne Faivre-Finn, MD

- **Abstract LBA8505:** Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). Charles M. Rudin, MD

- **Abstract 8507:** E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC—Outcomes based on chemotherapy subsets. Heather A. Wakelee, MD

11:30 - 12:00  Coffee Break
Friday 2nd of September 2016

16:45 - 17:30  Head & Neck Cancer

Speakers: TBA
Chairs: TBA

- **Abstract LBA2:** A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). James R. Perry, MD

- **Abstract 6000:** Induction docetaxel platinum 5-FU (TPF) followed by cetuximab-radiotherapy (cetux-RT) versus concurrent chemo-radiotherapy (CT/RT) in patients with N2b/c-N3 non operated stage III-IV squamous cell cancer of the head and neck (SCCHN): Results of the GORTEC 2007-02 phase III randomized trial. Lionnel Geoffrois, MD

- **Abstract 6007:** Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial. Li Zhang, MD

- **Abstract 6009:** Nivolumab versus therapy of investigator’s choice (IC) for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. Robert L. Ferris, MD

- **Abstract 6011:** Preliminary results from KEYNOTE-055: pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC). Joshua Bauml, MD
Saturday 3rd of September 2016

08:00  Registration

09:00 - 10:00  Gastrointestinal (Colorectal) Cancer

Speakers: TBA  
Chairs: TBA

- **Abstract 3503**: NCI9673: A Multi-Institutional ETCTN Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal (SCCA). Van Karlyle Morris II, MD

- **Abstract 3504**: Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). Alan P. Venook, MD

- **Abstract 3507**: CREST: Randomised phase III study of stenting as a bridge to surgery in obstructing colorectal cancer—Results of the UK ColoRectal Endoscopic Stenting Trial (CREST). James Hill, MD

- **Abstract 3511**: The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers. Jeanne Tie, MD

- **Abstract 3512**: FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized study - Prodigie 14 – Accord 21 (METHEP-2), a UNICANCER GI trial. Marc Ychou, MD
**Saturday 3rd of September 2016**

**10:00 - 11:00**  **Gastrointestinal (Noncolorectal) Cancer**

*Speakers:* TBA  
*Chairs:* TBA

- **Abstract 4000:** A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study. Marcel Verheij, MD

- **Abstract LBA4001:** FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. Salah-Eddin Al-Batran, MD

- **Abstract 4003:** Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)- CALGB 80802 (Alliance). Ghassan K. Abou-Alfa, MD

- **Abstract 4005:** NETTER-1 Phase III: Efficacy and Safety Results in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate. Jonathan R. Strosberg, MD

- **Abstract LBA4006:** ESPAC-4: A multicenter, international, open label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. John P. Neoptolemos, MD

**11:00 - 11:15**  **Coffee Break**
Saturday 3rd of September 2016

11:15 - 12:15  Genitourinary (Prostate) Cancer

Speakers: TBA
Chairs: TBA

- Abstract 5001: A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12. Goran Ahlgren, MD

- Abstract 5003: A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. Charles N. Catton, MD

- Abstract 5004: Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805). Linda J. Patrick-Miller, MD

- Abstract 5006: Cabazitaxel vs docetaxel in chemotherapy-naïve (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A 3-arm phase III study (FIRSTANA). Oliver Sartor, MD

- Abstract 5008: Phase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D). Johann de Bono, MD
Saturday 3rd of September 2016

12:15 - 13:00  Genitourinary (Nonprostate) Cancer

Speakers: TBA
Chairs: TBA

- **Abstract 4503:** Limited versus extended pelvic lymphadenectomy in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial (LEA AUO AB 25/02). **Juergen E. Gschwend, MD**

- **Abstract 4506:** Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC). **Toni K. Choueiri, MD**

- **Abstract LBA4500:** Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1. **Arjun Vasant Balar, MD**

13:00 - 14:00  Lunch Break
Saturday 3rd of September 2016

14:00 - 15:00    Gynecologic Cancer

Speakers: TBA
Chairs: TBA

- **Abstract 5501**: Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis. **Jonathan A. Ledermann, MD**

- **Abstract LBA5503**: OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) vs. intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC). **Helen Mackay, MD**

- **Abstract 5507**: Performance characteristics and stage distribution of invasive epithelial ovarian/tubal/peritoneal cancers in UKCTOCS. **Usha Menon, MD**

- **Abstract 5508**: Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG Symptom Benefit Study (SBS). **Felicia Roncolato, MD**
Saturday 3rd of September 2016

15:00 - 15:30   Developmental Therapeutics

Speakers: TBA
Chairs: TBA

- **Abstract 100**: CheckMate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC). Scott Joseph Antonia, MD

- **Abstract 2500**: Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors. David Michael Hyman, MD

- **Abstract 2503**: Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors. Sara M. Tolaney, MD

- **Abstract 3003**: Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology. Luis A. Diaz Jr., MD

- **Abstract 3001**: CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. Matthew David Hellmann, MD
Saturday 3rd of September 2016

15:30 - 16:15  Melanoma / Skin Cancers

Speakers: TBA
Chairs: TBA

- **Abstract 9502**: Genomic analysis and 3-γ efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. Keith T. Flaherty, MD

- **Abstract 9503**: 3-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Caroline Robert, MD

- **Abstract 9504**: Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006. Jacob Schachter, MD

- **Abstract 9505**: Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). Jedd D. Wolchok, MD

- **Abstract 9506**: Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort. Georgina V. Long, MD
Saturday 3rd of September 2016

16:15 - 17:00   Patient and Survivor Care

Speakers: TBA
Chairs: TBA

- **Abstract 10000**: A URCC NCORP nationwide randomized controlled trial investigating the effect of exercise on chemotherapy-induced peripheral neuropathy in 314 cancer patients. **Ian Kleckner, MD**

- **Abstract 10001**: Comorbidities and risk of chemotherapy induced peripheral neuropathy among participants in SWOG clinical trials. **Dawn L. Hershman, MD**

- **Abstract 10003**: Randomized trial of early integrated palliative and oncology care. **Jennifer S. Temel, MD**

- **Abstract 10006**: Benefits of Physician Orders for Scope of Treatment (POST) forms on end-of-life care in cancer patients: Insights from the West Virginia registry. **Mark W. Knestrick, MD**

- **Abstract 10019**: Placebo-controlled phase III study comparing dexamethasone on day1 to on day1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy. **Kunihiro Matsuzaki, MD**